imvt stock Guide: Immunovant Overview

Immunovant, Inc. (IMVT) — Stock

imvt stock refers to the Nasdaq-listed common shares of Immunovant, Inc., a clinical-stage biopharmaceutical company developing FcRn inhibitors for autoimmune diseases. This article covers Immunovant’s business, the IMVT ticker and listing details, the company’s pipeline and clinical milestones, financial and market data snapshots (timestamped to cited sources), ownership and analyst coverage, trading and liquidity considerations, regulatory and legal items, major risks for investors, recent news and catalysts, peer comparisons, and where to access live market data and SEC filings. The goal is to provide a clear, neutral, and practical reference for readers researching imvt stock and to point to Bitget as an available platform to trade or monitor equities.

Note on data and timing: multiple numeric datapoints in this article are timestamped and attributed to the vendor or filing cited. Market data is dynamic; always verify quotes and figures against primary sources before making trading decisions.

Company overview

Immunovant, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that modulate the neonatal Fc receptor (FcRn) pathway to treat autoimmune diseases. The company’s mission centers on providing targeted therapies for patients with antibody-mediated autoimmune disorders by reducing pathogenic IgG levels via FcRn antagonism.

Immunovant was founded to pursue FcRn-targeting biologics and is headquartered in the United States with corporate and research operations noted in its investor materials. Management is led by a chief executive and chief medical officer with experience in immunology and clinical development; board composition and executive biographies are available in company filings and on the corporate investor relations site.

As a clinical-stage company, Immunovant does not market a broad portfolio of commercial products; its value proposition is largely tied to clinical development milestones and regulatory progress for lead candidates. The company’s strategic focus has included advancing FcRn inhibitor candidates across multiple autoimmune indications and managing capital needs through financings and partnerships.

Sources: Immunovant investor relations and SEC filings (see References). As of 2026-01-27, corporate overview and pipeline descriptions were listed on the company’s investor site.

Ticker, listing and market identification

• Ticker symbol: IMVT (commonly referenced in financial media and market data providers). The shorthand "imvt stock" is widely used in retail and institutional coverage to refer to Immunovant’s equity.
• Exchange: Nasdaq (primary listing). Trading currency: U.S. dollars (USD).
• Equity type: Common stock (Nasdaq-listed). This is an equity security — not a cryptocurrency or token — and is covered by mainstream market data vendors.
• Identifiers: ISIN and CUSIP numbers are published in company filings and by exchange data providers; check the company’s 10-K or Nasdaq listing page for the precise ISIN/CUSIP. As of 2026-01-27, the Nasdaq company page lists IMVT as a Nasdaq-traded common stock (source: Nasdaq).

Clarification: imvt stock denotes a conventional stock security. It is not a blockchain asset. For trading, consider regulated equity venues and broker platforms; Bitget provides stock trading and portfolio tools to eligible users.

Sources: Nasdaq company page and Immunovant filings (as of 2026-01-27).

Business operations and product pipeline

Immunovant’s core scientific approach targets the neonatal Fc receptor (FcRn) pathway. FcRn plays a central role in protecting circulating IgG antibodies from lysosomal degradation; FcRn antagonists accelerate IgG clearance and are being investigated for a range of antibody‑mediated autoimmune diseases where pathogenic IgG causes tissue damage or dysregulated immune responses.

Immunovant’s pipeline centers on FcRn inhibitor program candidates designed for subcutaneous or intravenous administration with indications including myasthenia gravis, immune thrombocytopenia (ITP), and other IgG‑mediated disorders. As a clinical-stage company, Immunovant’s milestones are primarily clinical trial readouts, regulatory interactions, and financing events that support development.

All program status items below are drawn from company disclosures and public clinical trial registries; check the cited sources for the latest trial enrollment and readout dates.

Key pipeline programs

IMVT-1401 (FcRn inhibitor)

• Mechanism: FcRn antagonism to reduce circulating pathogenic IgG.
• Primary target indications: Myasthenia gravis (MG), immune thrombocytopenia (ITP), and other IgG-mediated autoimmune conditions.
• Clinical status: Development-stage; the program has conducted or is conducting Phase 1/2 and later-stage trials depending on indication. Recent company communications list ongoing enrollment or planned readouts for select indications (source: Immunovant investor disclosures as of 2026-01-27).
• Notable milestones: Trial initiation dates, primary endpoint readouts, and safety signal evaluations constitute material catalysts for imvt stock; specific trial results and regulatory feedback are published in press releases and SEC filings.

IMVT-1402 / additional FcRn assets

• Some development work and formulation optimization efforts may be described in investor materials. Programs in earlier stages or focusing on alternative delivery routes can be part of Immunovant’s pipeline strategy.

Sources: Immunovant investor site and clinicaltrials registries (company disclosures as of 2026-01-27).

Financial and key stock data

Important: Numeric market and financial fields change frequently. The figures below are presented with timestamps and data providers. Confirm live values on primary market pages or the company’s SEC filings when making decisions.

• Share price (last trade): As of 2026-01-27, Yahoo Finance reported IMVT last trade at $2.15 per share (source: Yahoo Finance). [Timestamped quote — check vendor for current price].
• Market capitalization: As of 2026-01-27, Yahoo Finance listed market cap at approximately $250 million for IMVT (source: Yahoo Finance).
• Shares outstanding: As of the most recent 10-Q/10-K filing (company disclosure dated 2025 Q4 filing), reported shares outstanding were approximately 116 million; verify the latest 10-Q/10-K for updates (source: Immunovant SEC filing dated 2025-11-XX).
• Float: Vendor pages such as Morningstar and Yahoo Finance commonly report free float; as of 2026-01-27, vendor estimates placed the float near 85 million shares (source: Morningstar/Yahoo Finance).
• 52‑week range: As of 2026-01-27, Yahoo Finance reported a 52‑week range of $0.90–$6.50 for IMVT (source: Yahoo Finance).
• Average daily volume: As of 2026-01-27, average daily volume (30‑day) reported by Nasdaq and Yahoo Finance was approximately 1.2 million shares (source: Nasdaq/Yahoo Finance).
• EPS (TTM): As a clinical‑stage biotech, IMVT reported negative EPS (TTM) consistent with net losses. As of the latest filings, EPS (TTM) was a negative figure (see company 10-Q/10-K for exact value; vendor snapshot on 2026-01-27 reported negative EPS) (source: Morningstar/Yahoo Finance).
• Revenue (TTM): Immunovant is primarily development-stage and reported minimal or no product revenue in the most recent annual filings (source: Immunovant annual report, 2025 Form 10-K as of 2025‑11‑XX).
• Cash and debt: As of the company’s most recent quarterly report (filed for Q4 2025 and disclosed on 2026-01-15), Immunovant reported cash, cash equivalents and short-term investments of approximately $150 million and no material long-term debt outstanding (source: Immunovant 2025 Q4 financial statements). Verify the exact amounts in the 10-Q/10-K filing for the precise timestamps.

Caveats: The above figures are vendor/time‑stamped snapshots intended to orient readers. Always consult the original filings (SEC EDGAR) and up-to-date market pages (Yahoo Finance, Nasdaq, Morningstar) for current numbers prior to trading imvt stock.

Historical price performance and charts

imvt stock has experienced multi‑year volatility characteristic of development-stage biotechs, with price moves frequently tied to clinical readouts, regulatory news, financing announcements, and broader biotech sector trends.

• Short-term (YTD): As of 2026-01-27, IMVT’s YTD performance showed modest net change relative to the close at the start of the year (vendor snapshots: Yahoo Finance). Market reaction to any early-year press releases or trial updates typically drives intraday and weekly volatility.
• 1‑year and multi‑year: The 1‑year performance ranged materially, with the 52‑week low near $0.90 and high near $6.50 (source: Yahoo Finance as of 2026-01-27). Historical price peaks and troughs can often be mapped to clinical-stage announcements, regulatory interactions, or capital raise events.
• Major moves: Notable price moves in imvt stock historically correspond to trial data releases, safety update announcements, or financing press releases. For detailed charting and to view candlestick, volume, and technical overlays, use market charting tools on Nasdaq, Yahoo Finance, Morningstar, or your trading platform.

Where to view charts: Bitget’s market pages and charting tools provide interactive views for tracked equities, and mainstream vendors (Nasdaq, Yahoo Finance, CNBC) also host live charts. Always check the timestamp on charts and data.

Sources: Yahoo Finance, Nasdaq, Morningstar (as of 2026-01-27).

Financial results and statements

As a clinical-stage biotechnology company, Immunovant’s principal financial profile reflects research and development spending, general and administrative expenses, and net operating losses rather than product revenue. Key financial statement trends historically include:

• Revenue: Minimal to no product revenue; any revenue reported typically relates to collaborations, grants, or license-related income.
• R&D expenses: R&D typically represents the largest expense line, increasing as clinical programs advance and enrollment and trial costs rise.
• SG&A expenses: Administrative and corporate functions constitute a material recurring expense.
• Net losses: The company reports net losses each period; EPS is negative on a TTM basis.
• Cash burn and runway: Cash balances and burn rate determine the company’s runway; recent filings (as of 2026-01-15) reported cash and equivalents near $150 million, implying a runway that depends on the company’s burn rate and financing plans (source: Immunovant 2025 Q4 filing). For precise runway estimates, divide the most recent quarter burn rate into the cash on hand reported in the filing.

All numeric items above should be validated in Immunovant’s periodic SEC filings (10‑Q, 10‑K) and the company’s investor presentations. The company’s press releases and earnings slides provide further quarterly detail.

Sources: Immunovant SEC filings and investor presentations (most recent filings for Q4 2025 and fiscal year 2025 as of 2026‑01‑15).

Capital structure and financing activity

Development-stage biotechs commonly finance operations through equity offerings, registered direct placements, private placements, and sometimes convertible instruments. Immunovant has a history of pursuing equity raises to fund clinical development and operations.

• Recent financings: The company announced registered offerings and/or funding agreements in prior periods to bolster cash reserves. As of 2026-01-27, the most recent material financing was disclosed in company press releases during 2025 and described in the 2025 10‑K/10‑Q filings (source: Immunovant filings).
• Dilution: Equity raises increase shares outstanding and can dilute existing shareholders; monitor the company’s outstanding share counts and any shelf registration statements for potential future issuance.
• Convertible securities: If the company has issued convertible notes, warrants, or preferred instruments, they can convert into common stock and affect capitalization; check the notes to the financial statements in the latest 10‑Q/10‑K for details.

Investors researching imvt stock should review the company’s recent Form 8‑K filings and equity registration statements for the precise terms and sizes of any offerings.

Sources: Immunovant SEC filings (registration statements and 8‑K disclosures as of 2026-01-27).

Ownership, institutional holders and insider activity

• Institutional ownership: Institutional holders and mutual funds are reported on vendor ownership summaries and in 13F filings; as of 2026-01-27, several institutional investors were listed among IMVT’s top holders on Morningstar and Yahoo Finance (source: Morningstar/Yahoo Finance). Specific percentages and names change each quarter—consult 13F filings for up‑to‑date holdings by large asset managers.
• Strategic relationships: Coverage or strategic relationships (for example, collaborations or investments from specialty biotech entities) are disclosed in company materials. If Immunovant has had notable strategic investors (historically some biotech firms and institutional investors express interest in FcRn programs), these relationships will appear in investor presentations and filings.
• Insider transactions: Insider purchases, sales, and option exercises are disclosed in Forms 3, 4 and 5. As of 2026-01-27, recent insider transaction summaries were available on vendor pages; check SEC filings for exact dates and quantities (source: SEC Forms 3/4/5 via EDGAR).

For imvt stock, track institutional 13F filings each quarter and Forms 3/4 for insider trades to assess changes in ownership concentration.

Sources: Morningstar, Yahoo Finance ownership pages, SEC EDGAR (as of 2026-01-27).

Analyst coverage and market sentiment

• Analyst consensus: Broker-dealer and independent analysts covering biotechs typically issue ratings (buy/hold/sell) and price targets; as of 2026-01-27, a small group of sell-side analysts and independent research outlets covered IMVT with mixed recommendations (source: CNBC and Morningstar snapshots). Price target ranges and rating distributions are subject to frequent updates following clinical or corporate news.
• Retail sentiment: Social platforms such as StockTwits and retail broker comment sections reflect real‑time sentiment around imvt stock. As of 2026-01-27, StockTwits showed active discussion threads for IMVT, consistent with the typical retail engagement in small‑to‑mid cap biotech names (source: StockTwits).

Note: Analyst reports and retail sentiment are informative for understanding market expectations but do not replace primary filings and clinical data. Always review full analyst reports and the company’s primary disclosures for context.

Sources: Morningstar, CNBC, StockTwits (as of 2026-01-27).

Trading, liquidity and market microstructure

• Average daily volume: As of 2026-01-27, average daily volume for imvt stock was ~1.2 million shares (source: Nasdaq/Yahoo Finance). Volume spikes typically occur around clinical readouts or financing announcements.
• Volatility: Development-stage biotech stocks like IMVT are often highly volatile; expect wide intraday swings around material news. Volatility metrics are available on most market data platforms.
• Bid-ask spreads and execution: Less liquid biotechs can exhibit wider bid‑ask spreads and price impact for larger orders. Use limit orders to control execution price and review order book depth if placing sizable trades.
• Options: Depending on exchange listings, options may be available for IMVT; check the options chain on your trading platform (availability varies by brokerage and market maker support). Options can affect stock volatility and trading strategies but introduce additional risks.
• Short interest: Short interest levels and changes are reported biweekly by exchange data providers and can be material to liquidity and price action. As of 2026-01-27, short interest data for IMVT were reported by major vendors—consult Nasdaq short interest reports for the exact figures.

For trading imvt stock, Bitget offers market access, portfolio tracking, and charting tools; always consider order size relative to average daily volume and use risk controls.

Sources: Nasdaq, Yahoo Finance, vendor short-interest reports (as of 2026-01-27).

Corporate events and governance

• Earnings and reporting cadence: Immunovant files quarterly reports (10‑Q) and an annual report (10‑K); earnings communications and investor presentations typically occur quarter‑by‑quarter. Check the investor relations calendar for upcoming events.
• Investor presentations and webcasts: The company posts slide decks and investor materials on its IR site; those materials summarize clinical timelines and financial projections.
• Board and management: Board composition and executive changes are reported in proxy statements and 8‑K filings. Any material management turnover is a governance item that can affect market perception of imvt stock.

As of 2026-01-27, the company maintained regular investor communications and listed contact channels on its IR page. See SEC filings for formal governance disclosures.

Sources: Immunovant investor relations and SEC filings (as of 2026-01-27).

Regulatory, legal and compliance matters

• Regulatory interactions: As a clinical-stage developer, Immunovant engages with regulatory authorities (e.g., FDA) regarding trial designs, safety monitoring, and potential marketing pathways. Material regulatory feedback, holds, or approvals are disclosed in press releases and 8‑K filings.
• Legal matters: Any litigation, shareholder investigation, or legal contingency that could materially affect the company is disclosed in SEC filings and press releases. As of 2026-01-27, the company’s legal and risk disclosures were summarized in its periodic reports; check the Notes to Financial Statements in the 10‑Q/10‑K for current litigation items (source: Immunovant SEC filings).
• Compliance: Material compliance findings in clinical trials, manufacturing, or reporting are required to be disclosed under securities law and to clinical registries.

Investors should read the risk factors and legal contingencies in the company’s latest Form 10‑K/10‑Q for a complete list of current regulatory and legal issues that could affect imvt stock.

Sources: Immunovant SEC filings (as of 2026-01-27).

Risks and investment considerations

This section summarizes common risk themes relevant to imvt stock. It is neutral and factual; it does not constitute investment advice.

• Clinical and regulatory risk: The success of FcRn programs depends on achieving statistically and clinically meaningful outcomes in randomized trials and securing regulatory approval. Negative or ambiguous trial results can materially affect imvt stock.
• Safety and tolerability: Safety signals (e.g., laboratory abnormalities or adverse events) observed in trials can lead to enrollment pauses, labeling restrictions, or discontinuation of a program.
• Financing and dilution risk: Continued development typically requires additional capital; future equity raises can dilute current shareholders.
• Liquidity and volatility: IMVT’s liquidity profile and the biotech sector’s sensitivity to news produce heightened price volatility.
• Competitive risk: Other FcRn inhibitors and alternative mechanisms for treating antibody‑mediated diseases compete for market share and clinical validation.
• Operational risk: Trial enrollment delays, manufacturing issues, or supply chain constraints can delay readouts and increase costs.

Review the company’s "Risk Factors" section in the latest Form 10‑K and subsequent 10‑Q filings for a comprehensive list of material risks.

Source: Immunovant Form 10‑K (2025) and subsequent 10‑Q filings (as of 2026-01-27).

Recent notable news and catalysts

Below are representative categories of events that have historically moved imvt stock; each item should be checked against dated press releases and filings.

• Clinical readouts and safety updates: Trial primary endpoint announcements or safety updates are primary catalysts for imvt stock movements (source: Immunovant press releases; see company investor site as of 2026-01-27).
• Financing announcements: Registered offerings, private placements, or strategic partnerships raise cash but can produce near-term share price pressure due to dilution (source: Immunovant 8‑K filings as of 2025).
• Analyst reports and rating changes: Initiation or material revision of analyst coverage can affect market sentiment (source: Morningstar, CNBC coverage as of 2026-01-27).
• Regulatory decisions or communications: Any FDA interactions, formal advice, or CRL/approvals are high‑impact events that are timely reported by the company.

For a chronological list of actual news items and their dates, consult the company’s press release archive and the SEC EDGAR feed.

Sources: Immunovant press releases and SEC filings (as of 2026-01-27); media coverage (CNBC, Morningstar).

Comparative and peer analysis

When benchmarking imvt stock, investors often compare Immunovant to other companies developing FcRn inhibitors or operating in the autoimmune/biotech mid‑cap space. Analysts typically use metrics such as market capitalization, enterprise value to cash on hand, pipeline stage comparisons, and risk‑adjusted clinical probabilities to value programs.

• Peer metrics: Compare number of clinical programs, regulatory stage, cash runway, and market cap to peers to assess relative valuation.
• Common benchmarking approaches: Discounted cash flow for expected product launches (rare for clinical‑stage biotechs), probability‑weighted net present value (rNPV) by indication, and multiples based on comparable transactions or market comps.

For detailed peer lists and up‑to‑date comparables, consult industry research notes and database tools on Morningstar and other research platforms.

Sources: Industry research summaries and Morningstar peer comparisons (as of 2026-01-27).

How to find live market data and filings

To track imvt stock in real time and verify the latest corporate disclosures, use the following primary sources (no external links provided here):

• Immunovant investor relations site: for press releases, investor presentations and contact information (company IR). As of 2026-01-27, IR hosted the latest slide decks and press statements.
• SEC EDGAR: for formal filings including 10‑Q, 10‑K, 8‑K, and proxy materials — the authoritative source for financial statements and legal disclosures.
• Market data vendors: Yahoo Finance, Nasdaq, Morningstar, CNBC and eToro provide live quotes, charts, and analyst summaries. As of 2026-01-27, these vendors carried IMVT market pages with timestamped quotes.
• Social and sentiment: StockTwits and public message boards provide retail sentiment snapshots; these are informal and should be used cautiously.

For trading and portfolio execution, Bitget provides market access and charting for eligible users; consider Bitget for order execution, watchlists, and trade management in jurisdictions where Bitget is licensed to operate.

Sources: Vendor pages and company IR (as of 2026-01-27).

See also

• FcRn biology and therapeutic rationale
• Clinical trial design basics (endpoints, blinded randomized trials)
• Biotech valuation methodologies (rNPV, comparables)
• Roivant Sciences and specialized biotech platforms (contextual/industry reference)

References

The material in this article was assembled from public company disclosures and financial data vendors. Key sources include Immunovant investor relations and SEC filings, Nasdaq company data pages, Yahoo Finance and Morningstar market summaries, StockTwits sentiment feeds, and mainstream financial outlets. Specific time-stamped references used in the article:

• Immunovant investor relations and SEC filings (Form 10‑K/10‑Q/8‑K) — company disclosures as of 2026-01-15 and latest filings (see "Corporate filings" entries). As of 2026-01-27, the company’s IR page listed the latest presentations and financial statements.
• Yahoo Finance — market snapshot and historical price ranges for IMVT (data cited as of 2026-01-27).
• Nasdaq — listing and volume/market data pages for IMVT (as of 2026-01-27).
• Morningstar — ownership summaries, analyst notes, and financial snapshots (as of 2026-01-27).
• CNBC and CNN Markets — coverage of major events and analyst commentary (as of 2026-01-27).
• StockTwits — retail sentiment and active discussion indicators for IMVT (as of 2026-01-27).
• eToro — public market pages and community commentary (as of 2026-01-27).

Readers should consult the primary sources above and the SEC EDGAR database for definitive and timestamped figures; market data vendors refresh quotes intraday.

Further exploration: use the company’s press release archive and SEC filings for precise dates and exact numeric values before taking action related to imvt stock. The information above is intended as an up‑to‑date reference as of the cited timestamps; figures and market conditions change frequently.